China the third Asian market to issue Augmentin recall over plasticiser concerns
This article was originally published in Scrip
China's State FDA has become the third regulator in Asia to issue a recall for GlaxoSmithKline's Augmentin (amoxicillin clavulanate) following the discovery of trace amounts of a plasticiser in an oral suspension formulation of the antibacterial.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.